ClinicalTrials.gov record NCT05198661

Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.The registry record was last updated on Feb 29, 2024, about 2 years ago, so the status shown may be out of date. The study team or the registry can confirm.
Study typeInterventionalA study in which researchers assign participants to one or more interventions, such as a drug, procedure, device, behavioural programme or other approach, to measure their effects.
SexAll
LocationFrance
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This study collects blood and, when available, leftover cerebrospinal fluid from people with paraneoplastic neurological syndromes or autoimmune encephalitis. Samples (serum, plasma, buffy coat, PBMCs and available CSF) are stored as a biocollection for research. The biocollection is assessed and kept for up to 10 years. The project is intended to support future research into diagnosis and treatment.

What it is studying. The study is creating and maintaining a biological sample collection (blood and available cerebrospinal fluid) from people with PNS or autoimmune encephalitis to support research on diagnosis and treatment.

What the researchers hope to learn. To build a biocollection of blood and cerebrospinal fluid for paraneoplastic neurological syndromes and autoimmune encephalitis to enable research, scientific collaborations, and publications aimed at improving diagnosis and treatment approaches.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

Numerous neurological disorders affecting the central and peripheral nervous system can be attributed to the immune system through multiple effector mechanisms. However, current treatments could be drastically improved by faster and more accurate diagnosis. The sample collection will benefit to patients with rare neuroimmune syndromes such as Autoimmune Encephalitis (AE) and Paraneoplastic Neurological Syndromes (PNS) leading to a better and early diagnosis, as well as treatment improvement.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Biological
  • Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • Patient with consent
  • Patient with well-characterized antibodies in serum or cerebrospinal fluid or not
  • Patient with neurological disorder compatible with PNS or auto-immune encephalitis

Exclusion criteria

  • Refusal of consent
  • Patient under guardianship

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

If you join, you would give informed consent and have a single blood draw to collect serum, plasma, buffy coat and peripheral blood mononuclear cells (PBMCs). If cerebrospinal fluid (CSF) was taken as part of your clinical care, any leftover CSF may be stored in the collection. Samples will be stored for research use as part of the biocollection; the registry describes assessing the biocollection over time.

How the study is structured. Interventional study that enrolls a single group of participants who give biological samples. There is no masking. Participants typically have a one-time blood draw; leftover cerebrospinal fluid from clinical care may be stored. Samples are tracked and kept for research purposes (primary outcomes measured over a 10-year collection period).

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • The listed sites are in France. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on autoimmune encephalitis

Clinical trials40 trials listed for autoimmune encephalitisEvery trial the registry lists for autoimmune encephalitis, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in autoimmune encephalitis researchLatest monthly update: September 2026. Includes: Efgartigimod reports. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start
Aug 2, 2022
Primary completion
Aug 2, 2032 (estimated)
Study completion
Aug 2, 2032 (estimated)
Target enrollment
3500 participants (estimated)
Last updated on registry
Feb 29, 2024
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
Hospices Civils de Lyon

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (62)

Terms used on this page · explanations by MedicalUpdates.ai

Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials